Antiangiogenic strategies in breast cancer management

Abstract Angiogenesis is considered one of the key mechanisms of tumour growth and survival. Therefore it represents an ideal pharmaceutical target. Many antiangiogenic agents have been developed so far in several solid tumours and also in breast cancer. Vascular endothelial growth factor (VEFG) is...

Full description

Saved in:
Bibliographic Details
Published in:Critical reviews in oncology/hematology 2010-10, Vol.76 (1), p.13-35
Main Authors: Giovannini, Monica, Aldrighetti, Daniela, Zucchinelli, Patrizia, Belli, Carmen, Villa, Eugenio
Format: Article
Language:English
Subjects:
Angiogenesis Inhibitors - pharmacology
Angiogenesis Inhibitors - therapeutic use
Animals
Antiangiogenic agents
Biological and medical sciences
Bisphosphonates
Breast cancer angiogenesis
Breast Neoplasms - drug therapy
COX-2 inhibitors
Female
Gynecology. Andrology. Obstetrics
Hematologic and hematopoietic diseases
Hematology, Oncology and Palliative Medicine
Hormonal therapy
Humans
Mammary gland diseases
Medical sciences
Metronomic chemotherapy
Monoclonal antibodies
Neovascularization, Pathologic - drug therapy
Tumors
Tyrosin kinase inhibitors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Abstract Angiogenesis is considered one of the key mechanisms of tumour growth and survival. Therefore it represents an ideal pharmaceutical target. Many antiangiogenic agents have been developed so far in several solid tumours and also in breast cancer. Vascular endothelial growth factor (VEFG) is the main target and both monoclonal antibodies and small molecules belonging to the tyrosine kinase inhibitors directed against VEGF(R) have been developed. Some other therapeutic approaches have shown to exert some antiangiogenic activity, such as hormonal agents, metronomic chemotherapy, bisphosphonates and others. In this paper we provide an introduction of the current data supporting the angiogenesis in breast cancer and a review of the most relevant antiagiogenic therapies which have been investigated so far.
ISSN:1040-8428
1879-0461
DOI:10.1016/j.critrevonc.2009.12.004